Repositório Científico do Instituto Nacional de Saúde >
Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis >
DPSPDNT - Artigos em revistas internacionais >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10400.18/323

Título: Familial hypercholesterolaemia in Portugal
Autor: Bourbon, M.
Alves, A.C.
Medeiros, A.M.
Silva, S.
Soutar, A.K.
Investigators of Portuguese FH Study
Palavras-chave: Familial hypercholesterolaemia
Low density lipoprotein receptor
Mutations
Coronary heart disease
Index patient
Cholesterol
Doenças Cardio e Cérebro-vasculares
Issue Date: Feb-2008
Editora: Elsevier
Citação: Atherosclerosis. 2008 Feb;196(2):633-42. Epub 2007 Aug 31
Resumo: Familial hypercholesterolaemia (FH) is characterised clinically by an increased level of circulating LDL cholesterol that leads to lipid accumulation in tendons and arteries, premature atherosclerosis and increased risk of coronary heart disease (CHD). Although Portugal should have about 20,000 cases, this disease is severely under-diagnosed in our country, this being the first presentation of Portuguese data on FH. A total of 602 blood samples were collected from 184 index patients and 418 relatives from several centres throughout Portugal. Fifty-three different mutations were found in 83 index patients, 79 heterozygous and 4 with two defective LDLR alleles. Additionally, 4 putative alterations were found in 8 patients but were not considered mutations causing disease, mainly because they did not co-segregate with hypercholesterolaemia in the families. Three unrelated patients were found to be heterozygous for the APOB(3500) mutation and two unrelated patients were found to be heterozygous for a novel mutation in PCSK9, predicted to cause a single amino acid substitution, D374H. Cascade screening increased the number of FH patients identified genetically to 204. The newly identified FH patients are now receiving counselling and treatment based on the genetic diagnosis. The early identification of FH patients can increase their life expectancy and quality of life by preventing the development of premature CHD if patients receive appropriate pharmacological treatment.
Arbitragem científica: yes
URI: http://hdl.handle.net/10400.18/323
ISSN: 0021-9150
Versão do Editor: http://www.sciencedirect.com/science/article/pii/S0021915007004546
Appears in Collections:DPSPDNT - Artigos em revistas internacionais

Files in This Item:

File Description SizeFormat
Familial hypercholesterolaemia in Portugal.pdf495,16 kBAdobe PDFView/Open
Statistics
FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpaceOrkut
Formato BibTex mendeley Endnote Logotipo do DeGóis 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

  © 2010 www.insa.pt - Todos os direitos reservados | Feedback Ministério da Saúde

Estamos no RCAAP Governo Português separator Ministério da Educação e Ciência  Fundação para a Ciência e a Tecnologia

Financiado por:

POS_C UE